Talquetamab gets top billing in Ash’s press programme, but the data raise important issues about the role of targeting GPRC5D.
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
DLL3, a pariah antigen after the implosion of Abbvie’s Rova-T, holds the interest of a handful of industry players.
Unveiled abstracts from Asco lift the stock of several biotechs, which will now be under pressure not to disappoint at the conference next week.
Sanofi’s latest acquisition sees the group pay $1bn for the private immuno-oncology company Amunix.
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.